Neurobiology of Aging
Volume 27, Issue 10 , Pages 1435-1439 , October 2006

Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer's disease

  • M. Ilyas Kamboh

      Affiliations

    • Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 412 624 3066; fax: +1 412 383 7844.
    • ,
  • Ryan L. Minster

      Affiliations

    • Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • ,
  • Margaret Kenney

      Affiliations

    • Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • ,
  • Ayla Ozturk

      Affiliations

    • Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • ,
  • Purnima P. Desai

      Affiliations

    • Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • ,
  • Candace M. Kammerer

      Affiliations

    • Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • ,
  • Steven T. DeKosky

      Affiliations

    • Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • Alzheimer's Disease Research Center, Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA

Received 3 May 2005 ,Revised 11 July 2005 ,Accepted 25 July 2005.

References 

  1. Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 1988;52:451–487
  2. Daw EW, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, et al. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet. 2000;66:196–204
  3. DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, Lopez OL, et al. Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann Neurol. 2003;53:81–90
  4. Haines JL, Pritchard ML, Saunders AM, Schildkraut JM, Growdon JH, Gaskell PC, et al. No genetic effect of α1-antichymotrypsin in Alzheimer disease. Genomics. 1996;33:53–56
  5. Higuchi M, Arai H, Nakagawa T, Higuchi S, Muramatsu T, Matsushita S, et al. Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and α1-antichymotrypsin type A allele in Alzheimer disease. Neuroreport. 1997;8:2639–2643
  6. Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis. 1995;112:145–159
  7. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST. APOE*4-associated Alzheimer's disease risk is modified by α1-antichymotrypsin polymorphism. Nat Genet. 1995;10:486–488
  8. Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004;62:2005–2009
  9. Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002;70:985–993
  10. Licastro F, Chiappelli M, Grimaldi LME , Morgan K, Kalsheker N, Calabrese E, et al. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol Aging. 2005;26:449–453
  11. Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pession A, et al. Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol. 2000;48:388–391
  12. Licastro F, Parnetti L, Morini MC, Davis LJ, Cucinotta D, Gaiti A, et al. Acute phase reactant α1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer's disease. Alzheimer Dis Assoc Disord. 1995;9:112–118
  13. Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated proteins α1-antitrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature. 1994;372:92–94
  14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  15. Morgan K, Licastro F, Tilley L, Ritchie A, Morgan L, Pedrini S, et al. Polymorphism in the alpha(1)-antichymotrypsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations. Hum Genet. 2001;109:303–310
  16. Mucke L, Yu GQ, McConlogue L, Rockenstein EM, Abraham CR, Masliah E. Astroglial expression of human α1-antichymotrypsi enhances Alzheimer's –like pathology in amyloid protein precursor transgenic mice. Am J Pathol. 2000;157:2003–2010
  17. Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, et al. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol Aging. 2004;25:1153–1167
  18. Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, et al. α1-Antichymotrypsin promotes β-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:1444–1451
  19. Nilsson LN, Das S, Potter H. Effect of cytokines, dexamethazone and the A/T-signal peptide polymorphism on the expression of alpha1-antichymotrypsin in astrocytes: significance for Alzheimer's disease. Neurochem Int. 2000;39:361–370
  20. Olson JM, Goddard KA, Dudek DM. A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum Genet. 2002;71:154–161
  21. Slooter AJC , Cruts M, Kalmijn S, Hofman A, Breteler MMB , van Broeckhoven C, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study. Arch Neurol. 1998;55:964–968
  22. Talbot T, Houlden H, Craddock N, Crook R, Hutton M, Lendon C, et al. Polymorphism in the AACT gene may lower age of onset of Alzheimer's disease. Neuroreport. 1996;7:534–536
  23. Wang YC, Liu HC, Liu TY, Hong CJ, Tsai SJ. Genetic association analysis of alpha-1-antichymotrypsin polymorphism in Parkinson's disease. Eur Neurol. 2001;45:254–256
  24. Yamada M, Sodeyama N, Itoh Y, Suematsu N, Otomo E, Matsushita M, et al. Association of alpha1-antichymotrypsin polymorphism with cerebral amyloid angiopathy. Ann Neurol. 1998;44:129–131
  25. Yoshiiwa A, Kamino K, Yamamoto H, Kobayashi T, Imagawa M, Nonomura Y, et al. α1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 carriers. Ann Neurol. 1997;42:115–117

PII: S0197-4580(05)00215-0

doi: 10.1016/j.neurobiolaging.2005.07.015

Neurobiology of Aging
Volume 27, Issue 10 , Pages 1435-1439 , October 2006

Article Tools

* Image Usage & Resolution